Combination therapy for malignant glioma based on PTEN status

Expert Review of Anticancer Therapy

Volumn 8, Issue 11, 2008, Pages 1767-1779

  Gonzalez, Javier ^a   de Groot, John ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combination treatment; Glioblastoma; P13K; PTEN; Targeted therapy

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BEVACIZUMAB; CARMUSTINE; CEDIRANIB; DASATINIB; DEFOROLIMUS; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; SORAFENIB; SUNITINIB; TANDUTINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; XL 184;

ADJUVANT THERAPY; ANGIOGENESIS; BRAIN SURGERY; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME ACTIVITY; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HUMAN; MONOTHERAPY; PHENOTYPE; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 60849098477     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.11.1767     Document Type: Review

References (89)

1. CBTRUS. 2008 statistical report: primary brain tumors in the United States, 1998-2002 (2008).
2. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190-198 (2001).
3. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
4. Fine HA, Kim L, Royce C et al. Results from Phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. Presented at: 42nd ASCO Annual Meeting. Orlando, FL, USA, 13-17 May 2005.
5. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018 (2002).
6. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase clinical trials. J. Clin. Oncol. 17, 2572-2578 (1999).
7. Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr. Opin. Oncol. 16, 607-613 (2004).
8. Louis DN. Molecular pathology of malignant gliomas. Annu. Rev. Pathol. 1, 97-117 (2006).
9. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947 (2004).
10. Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node - an intercept point for the control of angiogenesis in brain tumors. Nat. Clin. Pract. Neurol. 3, 682-693 (2007).
11. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22, 2954-2963 (2004).
12. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and crosstalks. Oncogene 27, 5527-5541 (2008).
13. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240-4245 (1999).
14. Smith JS, Tachibana I, Passe SM et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl Cancer Inst. 93, 1246-1256 (2001).
15. Duerr EM, Rollbrocker B, Hayashi Y et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16, 2259-2264 (1998).
16. Baeza N, Weller M, Yonekawa Y et al. PTEN methylation and expression in glioblastomas. Acta Neuropathol. 106, 479-485 (2003).
17. Wiencke JK, Zheng S, Jelluma N et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neurao Oncol. 9, 271-279 (2007).
18. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin. Cancer Res. 9, 3369-3375 (2003).
19. Kato H, FujimuraM, Kumabe T et al. PTEN genc mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J. Clin. Neurosci. 11, 37-41 (2004).
20. Sano T, Lin H, Chen X et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 59, 1820-1824 (1999).
21. Sasaki H, Zlatescu MC, Betensky RA et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am. J. Pathol. 159, 359-367 (2001).
22. Ermoian RP, Furniss CS, Lamborn KR et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 8, 1100-1106 (2002).
23. Kita D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastornas. Acta. Neuropathol. 113, 295-302 (2007).
24. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221-1224 (2004).
25. Gallia GL, Rand V, Siu IM et al. PIK3CA gene mutations in pediatric and adult glioblastorna multiforme. Mol. Cancer Res. 4, 709-714 (2006).
26. McLendon R. Friedman A, Bigner D et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature DOI:10.1038/nature07385 (2008) (Epub ahead of print).
27. Kita. D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 113, 295-302 (2007).
28. Wang AJ, Bigner SH, Bigner DD et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA 84(19), 6899-6903 (1987).
29. Fuller GN, Bigner SH. Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat. Res. 276, 299-306 (1992).
30. Li B, Yuan M, Kim IA et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23, 4594-4602 (2004).
31. Prados MD, Lamborn KR, Chang S et al. Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 8, 67-78 (2006).
32. Vogelbaum MA, Peereboom. DM, Stevens G et al. Phase II study of erlotinib single agent therapy in recurrent glioblastoma. Eur. J. Cancer 3(Suppl.), 135 (2005).
33. Raizer J, Abrey, LE, Wen T et al. A Phase II trial of erlotinib (OSI-774) patients with recurrent malignant gliomas (MG) not on EIAEDs. Am. Soc. Clin. Oncol. Annu. Meet. 22, 1502 (2004).
34. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22, 133-142 (2004).
35. Lieberman F, Qoughesy T, Malkin M et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Proc. Am. Soc. Clin. Oncol. 22, 105 (2003).
36. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
37. Haas-Kogan DA, Prados MD, Lamborn KR et al. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 4, 1369-1372 (2005).
38. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97, 880-887 (2005).
39. Van Den Bent MJ BA, Rampling R, Kouwenhoven M et al. Randomized Phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. Proc. Am. Soc. Clin. Oncol. 25, 2005 (2007).
40. Franceschi E, Cavallo G, Lonardi S et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre Phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia. (GICNO). Br. J. Cancer 96, 1047-1051 (2007).
41. de Groot JF, Gilbert MR, Aldape K et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neurooncol. 90(1), 89-97 (2008).
42. Brown PD KS, Sarkaria J, Wu W et al. A Phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM). J. Clin. Oncol. 26(20 Suppl.) Abstract 2016 (2008).
43. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
44. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 65, 7429-7435 (2005).
45. Maher EA, Furnari FB, Bachoo RM et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15, 1311-1333 (2001).
46. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: P13K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther. 4, 105-128 (2004).
47. Martin KA, Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv. Cancer Res. 86, 1-39 (2002).
48. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 103, 253-262 (2000).
49. Chang SM, Kuhn J, Wen P et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs 22, 427-435 (2004).
50. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J. Clin. Oncol. 23, 5294-5304 (2005).
51. Cloughesy TF, Yoshimoto K, Nghiemphu P et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5, e8 (2008).
52. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
53. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 5, 649-659 (2006).
54. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
55. Vredenburgh JJ, Desjard ins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253-1259 (2007).
56. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
57. Jain RK. Normalization of tumor vasculature: an emerging concept in anti-angiogenic therapy. Science 307, 58-62 (2005).
58. Wang MY, Lu KV, Zhu S et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66, 7864-7869 (2006).
59. Reardon DA, Quinn JA, Vredenburgh JJ et al. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 12, 860-868 (2006).
60. Doherty L, Gigas DC, Kesari S et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67, 156-158 (2006).
61. Wan X, Harkavy B, Shen N et al. Rapamycin induces feedback activation of Akt signaling through an IGF-IR-dependent mechanism. Oncogene 26, 1932-1940 (2007).
62. Liu TJ, LaFortune T, Honda T et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol. Cancer Ther. 6, 1357-1367 (2007).
63. Camphausen K, Tofilon PJ. Combining radiation and molecular targeting in cancer therapy. Cancer Biol. Ther. 3, 247-250 (2004).
64. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int. J. Radiat. Oncol. Biol. Phys. 58, 927-931. (2004).
65. Sartor CI. Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors. Nat. Clin. Pract. Oncol. 1, 80-87 (2004).
66. Delmas C, Heliez C, Cohen-Jonathan E et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer 100, 43-48 (2002).
67. Krishnan S, Brown PD, Ballman KV et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int. J. Radiat. Oncol. Biol. Phys. 65, 1192-1199 (2006).
68. Chakravarti A, Berkey B, Robins HI et al. An update of Phase II results from RTOG 0211: a Phase I/II study of gefitinib with radiotherapy in newly-diagnosed glioblastoma multiforme. Presented at: American Association for Cancer Researcb: 97th Annual Meeting. Washington, DC, USA, 1-5 April 2006.
69. Uhm JH, Ballman KV, Giannini C et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. J. Clin. Oncol. 22, 14S (2004) (Abstract 1505).
70. Edwards LA, Verreault M, Thiessen B et al. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol. Cancer Ther. 5, 645-654 (2006).
71. Shingu T, Yamada K, Hara N et al. Growth inhibition of human malignant glioma cells induced by the P13-K-specific inhibitor. J. Neurosury. 98, 154-161 (2003).
72. Maira. SM, Stauffer F, Brueggen J et al, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
73. Ziegler DS, Wright RD, Kesari S et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J. Clin. Invest. 118, 3109-3122 (2008).
74. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
75. Fan QW, Knight ZA, Goldenberg DD et al. A dual P13 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349 (2006).
76. Fan QW, Cheng CK, Nicolaides TP et al. A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67, 7960-7965 (2007).
77. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007).
78. Bredel M. Predicting outcome and tailoring treatment in high-grade gliomas. Lancet Oncol. 4, 269-270 (2003).
79. Bredel M, Bredel C, Juric D et al. Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas. J. Clin. Oncol. 24, 274-287 (2006).
80. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8. 1277-1280 (1990).
81. van den Boom J, Wolter M, Kuick R et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am. J. Pathol. 163, 1033-1043 (2003).
82. Phillips US, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glionia predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006).
83. Wen PY, Schiff D, Kesari S et al. Medical management of patients with brain tumors. J. Neurooncol. 80, 313-332 (2006).
84. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76, 22-76 (2005).
85. Dai H, Marbach P, Lemaire M et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther. 304, 1085-1092 (2003).
86. Jain RK. Anti-angiogenic therapy for cancer: current and emerging concepts. Oncology 19, 7-16 (2005).
87. Ma J, Li S, Reed K et al. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. j. Pharmacol. Exp. Ther. 305, 833-839 (2003).
88. Ma J, Pulfer S, Li S et al. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 61, 5491-508 (2001).
89. Zhou Q, Guo P, Gallo jM. Impact of angiogenesis inhibition by sunitinib on tumor distribunon of temozolomide. Clin. Cancer Res. 14, 1540-1549 (2008).